Ionis Pharmaceuticals Inc  

(Public, NASDAQ:IONS)   Watch this stock  
Find more results for Isis
+1.22 (3.69%)
After Hours: 34.20 -0.05 (-0.15%)
Feb 11, 4:14PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.93 - 35.25
52 week 30.93 - 77.80
Open 32.40
Vol / Avg. 2.69M/1.98M
Mkt cap 4.10B
P/E 308.28
Div/yield     -
EPS 0.11
Shares 120.12M
Beta 2.07
Inst. own 88%
Mar 15, 2016
Ionis Pharmaceuticals Inc at Barclays Global Healthcare Conference - 2:35PM EDT - Add to calendar
Mar 14, 2016
Ionis Pharmaceuticals Inc at ROTH Conference Add to calendar
Mar 9, 2016
Ionis Pharmaceuticals Inc at Cowen Health Care Conference - 8:00AM EST - Add to calendar
Feb 25, 2016
Q4 2015 Ionis Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Feb 11, 2016
Ionis Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference
Jan 11, 2016
Ionis Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 1, 2015
Isis Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Nov 18, 2015
Isis Pharmaceuticals Inc at Stifel Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -72.83% -18.20%
Operating margin -98.00% -26.16%
EBITD margin - -17.90%
Return on average assets -14.61% -4.32%
Return on average equity -52.59% -12.26%
Employees 390 -
CDP Score - -


2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases, including cardiovascular; metabolic; severe and rare diseases, including neurological disorders, and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels, including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs, nusinersen, volanesorsen and IONIS-TTR to the market. Its lipid-lowering product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen, IONIS-DMPK-2.5, Plazomicin and IONIS-GCGR.

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President - Legal, General Counsel
Age: 41
Bio & Compensation  - Reuters
C. Frank Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 58
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 57
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 53
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters